R&D Performance in the Pharmaceutical Industry: A Case Study of Egypt
Abstract
In Egypt, knowledge production function estimation using firm-level panel data indicates weak R&D performance in pharmaceutical firms. At the micro-level, in-depth interviews with selected pharmaceutical firms reveal a low R&D intensity, in addition to an inconsistent pattern of spending over time. Firms undertake piecemeal research projects, thus lacking a long term research vision. They put greater emphasis on R&D of the ‘development’ rather than the ‘basic’ or ‘applied’ types. Other symptoms of weakness are: modest collaboration with universities in research; modest collaboration with other firms in research and/or intellectual property; and a poor capacity to innovate. At the macro level, the public R&D system lacks good governance and sound coordination between research institutions. At both micro- and macro-levels, R&D efforts hinder innovation, thus hindering Egypt’s sustainable development and integration in today’s knowledge-based economy.
Â
Keywords: research and development, output, pharmaceutical industry, knowledge production function, in-depth interviews
This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License.
Authors of articles published in the European Journal of Sustainable Development retain copyright on their articles. Authors are therefore free to disseminate and re-publish their articles, subject to any requirements of third-party copyright owners and subject to the original publication being fully cited. The ability to copy, download, forward or otherwise distribute any materials is always subject to any copyright notices displayed. Copyright notices must be displayed prominently and may not be obliterated, deleted or hidden, totally or partially.